Nattokinase for prevention of thrombosis

A brief, sober pharmacy-journal review of nattokinase as a thrombosis-prevention agent — and a useful counterweight to the supplement’s more breathless promoters.

The authors acknowledge nattokinase’s genuine fibrinolytic (clot-dissolving) activity in biochemical and preliminary studies, but their tone is cautious: human clinical-trial data are scant, and they explicitly advise restraint until better evidence exists. It’s a measured “promising but unproven” assessment.

The practical takeaway is caution: nattokinase may appeal as a natural alternative to anticoagulants, but the evidence doesn’t yet support recommending it for that purpose. The status-quo angle — a cheap supplement potentially competing with prescription anticoagulants — is noted but not oversold.

We rate the evidence low: a short (12-reference) review leaning on preliminary data, without conflict disclosures or human-trial support. Its clinical significance is low — insufficient evidence for practical recommendations. Notably, its caution has aged well: it’s among the more honest nattokinase entries in our library, closer in spirit to the later rigorous meta-analysis (Li et al., 2023) than to the supplement’s advocacy pieces.